Mirabella Financial Services LLP Invests $5.48 Million in Standard BioTools Inc. (NASDAQ:LAB)

Mirabella Financial Services LLP acquired a new position in shares of Standard BioTools Inc. (NASDAQ:LAB - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 3,130,190 shares of the company's stock, valued at approximately $5,478,000. Mirabella Financial Services LLP owned approximately 0.84% of Standard BioTools at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of LAB. Takeda Pharmaceutical Co. Ltd. purchased a new stake in shares of Standard BioTools during the fourth quarter worth about $29,000. Cibc World Markets Corp purchased a new stake in Standard BioTools in the 4th quarter worth approximately $48,000. Simon Quick Advisors LLC purchased a new stake in Standard BioTools in the 4th quarter worth approximately $54,000. KLP Kapitalforvaltning AS acquired a new position in Standard BioTools in the 4th quarter valued at $70,000. Finally, HighTower Advisors LLC lifted its stake in shares of Standard BioTools by 13.0% during the 4th quarter. HighTower Advisors LLC now owns 92,791 shares of the company's stock worth $162,000 after purchasing an additional 10,690 shares during the period. 53.74% of the stock is currently owned by institutional investors and hedge funds.

Standard BioTools Stock Down 6.9 %

Shares of LAB stock traded down $0.09 during trading hours on Friday, hitting $1.15. 411,252 shares of the company were exchanged, compared to its average volume of 2,233,596. Standard BioTools Inc. has a 1 year low of $0.97 and a 1 year high of $2.74. The firm has a fifty day moving average of $1.16 and a 200 day moving average of $1.57. The firm has a market cap of $433.94 million, a PE ratio of -1.61 and a beta of 1.54.

Insiders Place Their Bets

In other news, Director Casdin Partners Master Fund, L purchased 4,820,959 shares of the company's stock in a transaction on Friday, February 28th. The stock was bought at an average cost of $1.06 per share, for a total transaction of $5,110,216.54. Following the completion of the purchase, the director now directly owns 58,846,780 shares of the company's stock, valued at $62,377,586.80. The trade was a 8.92 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 53.10% of the stock is currently owned by insiders.

Analyst Ratings Changes

Separately, KeyCorp downgraded Standard BioTools from an "overweight" rating to a "sector weight" rating in a research report on Thursday, February 27th.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.